Amsterdam, The Netherlands (ots/PRNewswire) -
- "Study Could Have Major Impact on the Decision-Making Process
With Respect to Infertility Treatment"
New data from an economic analysis presented today at this year's
European Society of Human Reproduction and Embryology (ESHRE)
congress showed that, within the parameters of the simulation model
used, the in vitro fertilisation (IVF) treatment MENOPUR
(highly-purified human menopausal gonatropin or HP-hMG) offered
considerable cost-savings over recombinant follicle stimulating
hormone (rFSH). The cost-effectiveness of HP-hMG compared with
rFSH suggested by this data could make it a more attractive choice
for use in infertility treatment within a fixed healthcare budget.
In today's difficult global financial situation, the
cost-effectiveness of infertility treatments, such as IVF, is more
important than ever. Experiencing fertility problems is deeply
distressing and isolating for couples and the cost of treatment is
one of many considerations for people seeking treatment. A recent
audit of European infertility patient groups showed that infertile
couples are calling for clear information on the cost-effectiveness,
as well as the efficacy of individual treatments.
HP-hMG and rFSH are two commonly used hormonal therapies
belonging to the class of drugs known as gonadotropins that enhance
egg production in IVF treatment. HP-hMG, contains both FSH and
hCG-driven (human chorionic gonadotropin) LH-activity (luteinizing
hormone). In contrast, rFSH is a recombinant product and contains
"Until recently, discussions regarding funding for infertility
treatment services have been hindered by a relative paucity of
economic studies of the specific treatments," points out study
investigator Dr Jaro Wex from PharmArchitecture, UK.
"Our new study compared success rates and value for money of
gonadotropins in IVF and this work is likely to have a major impact
on the decision-making process with respect to IVF treatment. The
study showed that HP-hMG is a more attractive option than rFSH within
a fixed budget, as it offers considerable cost savings over rFSH, not
only in terms of costs per treatment cycle, but also in costs per
Health economic data
The new study determined the cost-effectiveness of different
gonadotropins in IVF cycles involving frozen embryo transfers using a
simulation model. The economic evaluation compared HP-hMG and rFSH
using individual patient data (n=986) pooled from two large,
randomised, multi- national, non-inferiority trials (EISG and
The simulation model used both live-birth data for the compared
products and published UK costs of IVF related medical resources. The
main objectives were to determine for each patient starting treatment
consisting of one fresh and up to two cryo or fresh cycles: (1)
number of live-births (2) average cost of treatment; (3) average cost
per live-birth; (4) incremental cost-effectiveness; (5) impact of
inclusion of maternal and neonatal costs arising from successful
After a sequence of one fresh and up to two frozen or fresh
cycles, the cumulative live-birth rate was 53.7% for HP-hMG and 44.6%
for rFSH (p<0.005). The use of HP-hMG resulted in a saving of GBP875
per patient cycle, a saving that could finance an additional
treatment for every seven treatments delivered. Furthermore, the
cost per IVF baby delivered with HP-hMG was GBP11,157, compared with
GBP14,227 for rFSH(p<0.001).
Within the context of this economic analysis, HP-hMG offered a
superior cost-effectiveness in producing live-births over rFSH in
women undergoing conventional IVF and, when available, frozen embryo
transfer cycles. Since this study attempts to realistically model
the actual situation in patients undergoing infertility management,
it is believed that it will have a major implication on the
decision-making process when choosing the appropriate gonadotropin
for ovarian stimulation.
"I think the cost-effectiveness of treatments is a real issue for
couples considering infertility treatment such as IVF today", says
Clare Lewis-Jones from Infertility Network UK. "Despite the economic
downturn, we see that couples will somehow find the money for
treatment, although many have to make sacrifices in order to do this
- it's a question of priorities and the opportunity of having a
family is an extremely high priority for infertile couples."
MENOPUR belongs to a class of drugs known as gonadotropins and
contains both FSH (follicle stimulating hormone) and hCG-driven
(human chorionic gonadotropin) LH-activity (luteinizing hormone).
HP-hMG is used to stimulate the development of multiple follicles in
women participating in an ART programme. HP-hMG is also used to treat
infertility in women caused by anovulation (low-level production of
eggs). MENOPUR is used by over 75,000 patients each year and is
currently licensed in over 50 countries across the world
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a research-driven, specialty
biopharmaceutical group active in global markets. The company
identifies, develops and markets innovative products in the areas of
reproductive health, urology, gastroenterology and endocrinology.
Ferring's fertility portfolio of treatments gives infertile couples
the chance to have babies and includes its flagship brand MENOPUR
(HP-hMG), a recognised high quality treatment for infertility.
Ferring has operating subsidiaries in over 45 countries. To learn
more about Ferring or our products please visit
1. Wex J et al. HP-hMG versus rFSH in a combination of fresh and
cryo cycles in IVF: success rates and economic implications ESHRE.
Amsterdam 2009, abstract number O-103.
2. 2009. Greenhouse Data on file
3. European and Israeli Study Group on Highly Purified Menotropin
versus Recombinant Follicle-Stimulating Hormone. Efficacy and safety
of highly purified menotropin versus recombinant follicle-stimulating
hormone in in vitro fertilization/intracytoplasmic sperm injection
cycles: a randomized, comparative trial. Fertil Steril 2002; 78(3):
4. Andersen AN, et al. Clinical outcome following stimulation
with highly purified hMG or recombinant FSH in patients undergoing
IVF: a randomized assessor-blind controlled trial. Human
Reproduction 2006 Dec; 21(12):3217-27.
5. Platteau et al. Reprod Biomed Online 2008; 17:190-8.
ots Originaltext: Ferring Pharmaceuticals A/S
Im Internet recherchierbar: http://www.presseportal.ch
Contact: For further information, please contact: Claire Pay / Louisa
Revill, Greenhouse Communications, +44-(0)20-7798-9922 /
+44-(0)20-7798-9900 / email@example.com or:
Helen Gallagher, Ferring Pharmaceuticals, +41-58-301-0051 /